Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ECC Regimen in Advanced Gastric/GEJ Cancer
NCT00130936Phase 2Terminated
- Sponsor
- American Health Staffing Group
- Start
- Oct 2005
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of capecitabine in gastric cancer (GC), gastroesophageal junction adenocarcinoma, sponsored by American Health Staffing Group. Started Oct 2005; status: terminated.
02
Drugs
capecitabine
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT00130936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00130936.